Reviva Pharmaceuticals Wins 2014 TiE50 Award

Wednesday, 06 February 2013 by

SAN JOSE, Calif.–(BUSINESS WIRE)–Reviva Pharmaceuticals is excited to announcetie50_logo_winner_2014 that it has been selected as a Winner for the prestigious 2014 TiE50 Awards at the organization’s annual entrepreneurial conference, TiEcon in Santa Clara, California on May 16, 2014. Returning for the sixth year in a row, this year’s TiE50 was open to all technology companies

SAN JOSE, Calif.–(BUSINESS WIRE)–Reviva Pharmaceuticals, Inc., (Reviva), a privately held pharmaceutical company focused on the discovery and development of new, safer and highly effective therapies for chronic indications, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration (FDA) for its lead, new investigational antipsychotic drug, RP5063. The FDA

TOP